Published 2 days ago • loading... • Updated 1 day ago

Five-Year Data Show Sustained Efficacy of Zanubrutinib in CLL With High Response Rates

Summary by Pharmacy Times

The data from the 5-year analysis of arm C validate and support the efficacy and safety of zanabrutinib for treatment-naïve patients with CLL/SLL harboring del(17p).

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All

Left

Center

Right

ajmc.com

First-Line Ibrutinib Effective in CLL/SLL With or Without Risk Factors

Real-world data show no significant differences in overall survival between patients with or without cytogenetic risk factors.

1 day ago

Read Full Article

Pharmacy Times

Five-Year Data Show Sustained Efficacy of Zanubrutinib in CLL With High Response Rates

The data from the 5-year analysis of arm C validate and support the efficacy and safety of zanabrutinib for treatment-naïve patients with CLL/SLL harboring del(17p).

1 day ago

Read Full Article